Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

Acadia Pharma (ACAD) Misses Q4 EPS by 1c; Offers FY23 Revenue Guidance

February 27, 2023 4:10 PM EST

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $136.5 million versus the consensus estimate of $134.23 million.

GUIDANCE:

Acadia Pharma sees FY2023 Nuplazid sales of $520-530 million, versus the... More